IMMUNOTARGETS AND THERAPY : Impact Factor & More
eISSN: 2253-1556pISSN: 2253-1556
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on IMMUNOTARGETS AND THERAPY
IMMUNOTARGETS AND THERAPY Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in IMMUNOTARGETS AND THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in IMMUNOTARGETS AND THERAPY
Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer \u2013 A Post Hoc Analysis of METIMMOX Trial Data
- 14 May 2026
- ImmunoTargets and Therapy
Context-Dependent Survival Associations Between Interleukin-13 Expression and Immunotherapy in Advanced Solid Tumors.
- 1 May 2026
- ImmunoTargets and therapy
B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer
- 1 May 2026
- ImmunoTargets and Therapy
Guillain-Barré Syndrome: Progress in Diagnosis, Biomarkers, Neuroimaging and Management
- 2 Apr 2026
- ImmunoTargets and Therapy
Circulating miR-148a-3p Correlates with Inadequate Induction Response in Pediatric Hodgkin Lymphoma
- 1 Apr 2026
- ImmunoTargets and Therapy
New Insights on IgA Nephropathy from the Perspective of Active Lesions and Systemic Inflammatory Responses.
- 1 Apr 2026
- ImmunoTargets and therapy
Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer \u2013 A Post Hoc Analysis of METIMMOX Trial Data
- 14 May 2026
- ImmunoTargets and Therapy
Context-Dependent Survival Associations Between Interleukin-13 Expression and Immunotherapy in Advanced Solid Tumors.
- 1 May 2026
- ImmunoTargets and therapy
B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer
- 1 May 2026
- ImmunoTargets and Therapy
Guillain-Barré Syndrome: Progress in Diagnosis, Biomarkers, Neuroimaging and Management
- 2 Apr 2026
- ImmunoTargets and Therapy
Circulating miR-148a-3p Correlates with Inadequate Induction Response in Pediatric Hodgkin Lymphoma
- 1 Apr 2026
- ImmunoTargets and Therapy
New Insights on IgA Nephropathy from the Perspective of Active Lesions and Systemic Inflammatory Responses.
- 1 Apr 2026
- ImmunoTargets and therapy
FAQs on IMMUNOTARGETS AND THERAPY
How long has IMMUNOTARGETS AND THERAPY been actively publishing? 
What is the publishing frequency of IMMUNOTARGETS AND THERAPY?
How many articles did IMMUNOTARGETS AND THERAPY publish last year?
What is the eISSN & pISSN for IMMUNOTARGETS AND THERAPY?
Who is the publisher of IMMUNOTARGETS AND THERAPY?
